Pirola Alice, De Mattia Elisa, Lizio Andrea, Sannicolò Giulia, Carraro Elena, Rao Fabrizio, Sansone Valeria, Lunetta Christian
NEuroMuscular Omnicentre, Fondazione Serena Onlus, Milan, Italy.
NEuroMuscular Omnicentre, Fondazione Serena Onlus, Milan, Italy.
Clin Neurol Neurosurg. 2019 Sep;184:105456. doi: 10.1016/j.clineuro.2019.105456. Epub 2019 Jul 29.
Amyotrophic lateral sclerosis (ALS) patients tend to develop progressive respiratory muscle weakness, leading to ventilatory failure and ineffective cough, principal causes of morbidity and mortality. Since patients are usually unaware of these symptoms, these are generally not noticed until the advanced stages and are associated with poor prognosis. The monitoring of respiratory function on a regular basis is therefore of great importance. Despite the availability of several pulmonary function tests, none of them was found to be the best indicator of the disease progression throughout the course of this condition. The main aim of our work was to evaluate the prognostic value of these respiratory measures evaluated in a brief period of observation and their correlation with motor functional impairments in an ALS cohort.
Patients with ALS who had respiratory assessments performed and functional motor scales administered at baseline and six months later were included. All patients were assessed with forced vital capacity, both in seated and supine position (FVC; sFVC), peak expiratory flow (PEF), peak expiratory cough flow (PCEF), the revised ALS functional rating scale (ALSFRS-R), at baseline and after six months, and their disease progression rate (ΔFS) was obtained.
We included 73 patients with probable or definite ALS according to El-Escorial revised Criteria. At baseline, PCEF and PEF significantly correlated with ALSFRS-R total, bulbar and spinal subscores and ΔFS, while FVC% significantly correlated with ΔFS. After 6 months all the respiratory parameters significantly correlated with ALSFRS-R and all its subscores. Longitudinally, FVC%, sFVC% and PCEF significantly correlated with ΔFS and some of ALSFRS-R subscores. As concerns the survival analysis, monthly declines of FVC% and sFVC%, significantly correlated with the survival. The worse prognosis in terms of survival was finally found in those whose FVC% and sFVC% dropped below their respective cut-offs.
Throughout the course of ALS disease, the monitoring of several respiratory markers, namely FVC, sFVC, PEF and PCEF, plays a critical role in predicting the prognosis of these subjects, both in terms of survival and functional ability. The implementation of monthly cut-offs in the evaluation of FVC and sFVC may allow a faster recognition of those patients with worse prognosis and therefore an optimized tailored clinical care, as well as a better stratification in clinical trials.
肌萎缩侧索硬化症(ALS)患者往往会出现进行性呼吸肌无力,导致呼吸衰竭和咳嗽无力,这是发病和死亡的主要原因。由于患者通常未意识到这些症状,所以这些症状一般直到疾病晚期才被注意到,且与预后不良相关。因此,定期监测呼吸功能非常重要。尽管有多种肺功能测试方法,但在该疾病的整个病程中,没有一种被发现是疾病进展的最佳指标。我们这项研究的主要目的是评估在短时间观察期内所评估的这些呼吸指标的预后价值,以及它们与一组ALS患者运动功能障碍的相关性。
纳入在基线期和6个月后进行了呼吸评估并接受运动功能量表测试的ALS患者。在基线期和6个月后,对所有患者进行坐位和仰卧位的用力肺活量(FVC;sFVC)、呼气峰值流速(PEF)、呼气咳嗽峰值流速(PCEF)以及修订的ALS功能评定量表(ALSFRS-R)评估,并计算其疾病进展率(ΔFS)。
根据El-Escorial修订标准,我们纳入了73例可能或确诊的ALS患者。在基线期,PCEF和PEF与ALSFRS-R总分、延髓和脊髓亚评分以及ΔFS显著相关,而FVC%与ΔFS显著相关。6个月后,所有呼吸参数均与ALSFRS-R及其所有亚评分显著相关。纵向来看,FVC%、sFVC%和PCEF与ΔFS以及部分ALSFRS-R亚评分显著相关。关于生存分析,FVC%和sFVC%的每月下降幅度与生存率显著相关。最终发现,FVC%和sFVC%降至各自临界值以下的患者预后较差。
在ALS疾病的整个病程中,对多种呼吸指标,即FVC、sFVC、PEF和PCEF进行监测,在预测这些患者的生存和功能能力预后方面起着关键作用。在评估FVC和sFVC时采用每月临界值,可能有助于更快地识别预后较差的患者,从而实现优化的个性化临床护理,并在临床试验中进行更好的分层。